Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Illumina, Inc.    ILMN


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

China's BGI gets Australian foothold through mass coronavirus test delivery

05/06/2020 | 03:53am EST
A technician works at a genetic testing laboratory of BGI, formerly known as Beijing Genomics Institute, in Kunming

By Kirsty Needham

Australia says its purchase of 10 million coronavirus test kits from Chinese genomics company BGI will not risk patient privacy, as researchers hope for greater price competition in a biotech market dominated by a U.S rival.

The deal was struck even as relations between Australia and China have been strained by Australia's call for a global enquiry into the coronavirus outbreak, which China has framed as a U.S.-led attempt to blame it for the pandemic.

BGI - Beijing Genomics Institute - has grown into one of the world's largest genomics companies in the two decades since it worked on the Human Genome Project. It has one lab in Australia and had been seeking to expand its genome sequencing services.

BGI, whose BGI Genomics Co is listed on the Shenzhen stock exchange, was named as having "evident links" to the Chinese government in a U.S. Trade Office report into Chinese technology transfer practices that was used to justify the U.S. imposition of tariffs on Chinese exports.

There are also concerns about its work in China, including providing gene technology used for surveillance of the Uighur ethnic minority in China's western Xinjiang region.

BGI is also defending multiple patent lawsuits from U.S. firm Illumina Inc, the dominant player in the Australian market.

But unlike the Australian government's move to effectively exclude Chinese telecom giant Huawei from its 5G network on national security grounds because of its perceived links to Beijing, security agencies have approved the mass use of BGI technology to combat the novel coronavirus.

Australian pathology companies have installed BGI's nucleic acid extraction machines in 11 laboratories, to process the tests automatically, BGI said in a statement.

A spokesman for Australian health minister Greg Hunt said privacy laws covered pathology tests and patient data, and the use of BGI equipment had been approved by security agencies.

"BGI will have no access to patient information as they will not be operating the labs," the spokesman said in a statement, with pathology companies required to comply with security agency advice on installing BGI's technology.

"The extent of BGI's involvement with existing Australian laboratories will be limited to the installation of COVID-19 pathology testing platforms and training of staff." 


Asked about privacy concerns, BGI Australia Director Bicheng Yang said Australian pathology labs would operate under national guidelines.

"BGI provided technology transfer and the equipment does not collect personal data. The process tests the viral RNA (ribonucleic acid) only, if it is present," Yang said in a statement to Reuters.

The technology used to test for the coronavirus is different from those used in the diagnosis of other rare diseases, cancer and birth defects in pregnancy, but the scale of the coronavirus programme will boost BGI's links with Australian laboratories, Australian researchers who work with BGI said.

Marcel Dinger, president of the Australian Genomics Technologies Association and a director of Pryzm Health, a data science company that develops rare disease diagnosis software, said most gene sequencing in Australia was supplied by Illumina.

"They have the lion's share by a long way in the market when it comes to genome sequencing. BGI have a fairly equivalent technology now ... They are really a competitor in the market with real potential to disrupt," he said.

BGI wants to bring the cost of sequencing a patient's whole genome down to a few hundred dollars, Dinger said.

"It would make genome sequencing more widely available".

BGI owns the China National Genebank, containing 11 million human, plant and animal DNA samples.

Australia does not have a national genome database because privacy concerns have stopped its development, Dinger said.

La Trobe University associate professor James Leibold said there were "larger ethical issues" associated with BGI, including data privacy, its use of the world's largest gene database, and providing gene technology for surveillance of the Uighurs in Xinjiang.

"They are a complex company that operates under a different ethical framework," Leibold, who is an expert in Uighur studies and is critical of the Australian health agency's decision to work with BGI, told Reuters.

Interactive graphic tracking global spread of coronavirus: open https://graphics.reuters.com/CHINA-HEALTH-MAP/0100B59S39E/index.html in an external browser

(Reporting by Kirsty Needham; Editing by Robert Birsel)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ACCESS CO., LTD. 1.39% 803 End-of-day quote.-15.92%
AMP LIMITED 0.88% 1.725 End-of-day quote.-9.92%
BGI GENOMICS CO., LTD. -2.88% 129.29 End-of-day quote.88.20%
BYD COMPANY LIMITED 0.81% 199.8 End-of-day quote.414.29%
HOPE, INC. 10.99% 6870 End-of-day quote.113.35%
ILLUMINA, INC. 1.25% 305.63 Delayed Quote.-7.87%
SHENZHEN STOCK EXCHANGE A SHARE INDEX -0.34% 2401.0294 Real-time Quote.33.67%
THE GLOBAL LTD. 8.48% 243 End-of-day quote.-48.41%
THE NEW HOME COMPANY INC. 2.74% 5.62 Delayed Quote.20.60%
WORLD CO., LTD. 2.47% 1330 End-of-day quote.-50.58%
All news about ILLUMINA, INC.
11/18ILLUMINA : to Webcast Upcoming Investor Conference Presentation
11/12ILLUMINA : Realize the Full Potential of the NextSeq 2000 with the Power of the ..
11/10ILLUMINA, INC. : Other Events (form 8-K)
10/30ILLUMINA : Management's discussion & analysis
10/29ILLUMINA : 3Q Earnings Snapshot
10/29ILLUMINA, INC. : Results of Operations and Financial Condition, Financial Statem..
10/29ILLUMINA : Reports Financial Results for Third Quarter of Fiscal Year 2020
10/29ILLUMINA, INC. : 3rd quarter results
10/26ILLUMINA, INC. : quaterly earnings release
10/20ILLUMINA, INC. : Report
More news
Financials (USD)
Sales 2020 3 168 M - -
Net income 2020 543 M - -
Net cash 2020 2 230 M - -
P/E ratio 2020 82,3x
Yield 2020 -
Capitalization 44 070 M 44 070 M -
EV / Sales 2020 13,2x
EV / Sales 2021 10,7x
Nbr of Employees 7 700
Free-Float 75,1%
Duration : Period :
Illumina, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 18
Average target price 303,88 $
Last Close Price 301,85 $
Spread / Highest target 25,9%
Spread / Average Target 0,67%
Spread / Lowest Target -17,2%
EPS Revisions
Francis A. deSouza President, Chief Executive Officer & Director
Jay T. Flatley Executive Chairman
Robert P. Ragusa Senior Vice President-Global Quality & Operations
Sam A. Samad Chief Financial Officer & Senior Vice President
Phillip G. Febbo Chief Medical Officer
Sector and Competitors